CNIH4

Across TCGA pan-cancer cohorts, CNIH4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CNIH4 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CNIH4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CNIH4 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

GBM, HNSC, and CCRCC are the cancer types where CNIH4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.819	0.614	.003	26	view →
HNSC	DFS	Tertile	All	1.000	0.922	.014	7	view →
CCRCC	DFS	Median	All	0.915	0.537	.003	6	view →
LUAD	OS	Median	III,IV	0.681	0.278	.037	2	view →
LSCC	OS	Tertile	All	1.000	0.950	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CNIH4–GBM (DFS)

Open the GBM breakdown →